Has Scott Horner, MD received payments from drug or device companies?

Yes. Drug and device makers reported $783 in general payments to Scott Horner, MD across 24 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Scott Horner, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Scott Horner, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Scott Horner, MD

Urology · Reading, PANPI 1902879661

Payments from drug & device makers

$783in general payments, 2019–2025

Across 24 payments — averaging $32.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bayer$392
Astellas Pharma US Inc$250
Johnson & Johnson$95
Ferring Pharmaceuticals Inc.$18
Merck$16
Pfizer$12

What the payments were for

Food & beverage$60477%
Education$17923%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bayer	9	$392
Astellas Pharma US Inc	6	$250
Johnson & Johnson	6	$95
Ferring Pharmaceuticals Inc.	1	$18
Merck	1	$16
Pfizer	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Nubeqa$260

How this compares

$783 in reported general payments places this provider in the 30th percentile of 596 urology providers in Pennsylvania.

See all urology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$110,558

Medicare patients

422

Services billed

1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	59	$47,383
GemtesaVibegron	29	$22,904
Abiraterone Acetate	14	$11,745
Doxazosin Mesylate	315	$6,825
Potassium Citrate ErPotassium Citrate	47	$5,278
Mirabegron ErMirabegron	11	$5,035
Tamsulosin Hcl	229	$4,003
Trospium Chloride	70	$3,665
Finasteride	101	$1,638
Testosterone Cypionate	20	$1,158
Oxybutynin Chloride	46	$811
Terazosin Hcl	33	$683
Bicalutamide	11	$579
Alfuzosin Hcl ErAlfuzosin Hcl	26	$552
Methenamine Hippurate	18	$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Astellas Pharma US IncMyrbetriq	$250	$47,38359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 596 urology providers in Pennsylvania.